6838 Stock Overview
A clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Formosa Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$41.95 |
52 Week High | NT$66.90 |
52 Week Low | NT$38.75 |
Beta | 1.01 |
11 Month Change | -23.03% |
3 Month Change | -21.29% |
1 Year Change | -16.10% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -25.09% |
Recent News & Updates
Recent updates
Shareholder Returns
6838 | TW Pharmaceuticals | TW Market | |
---|---|---|---|
7D | -6.7% | 8.0% | 6.5% |
1Y | -16.1% | 13.3% | 31.4% |
Return vs Industry: 6838 underperformed the TW Pharmaceuticals industry which returned 15.9% over the past year.
Return vs Market: 6838 underperformed the TW Market which returned 31.7% over the past year.
Price Volatility
6838 volatility | |
---|---|
6838 Average Weekly Movement | 6.3% |
Pharmaceuticals Industry Average Movement | 5.4% |
Market Average Movement | 5.7% |
10% most volatile stocks in TW Market | 9.4% |
10% least volatile stocks in TW Market | 2.9% |
Stable Share Price: 6838's share price has been volatile over the past 3 months.
Volatility Over Time: 6838's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | Erick Co | www.formosapharma.com |
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer.
Formosa Pharmaceuticals, Inc. Fundamentals Summary
6838 fundamental statistics | |
---|---|
Market cap | NT$5.63b |
Earnings (TTM) | -NT$321.96m |
Revenue (TTM) | NT$31.17m |
180.5x
P/S Ratio-17.5x
P/E RatioIs 6838 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6838 income statement (TTM) | |
---|---|
Revenue | NT$31.17m |
Cost of Revenue | NT$3.83m |
Gross Profit | NT$27.35m |
Other Expenses | NT$349.30m |
Earnings | -NT$321.96m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.40 |
Gross Margin | 87.73% |
Net Profit Margin | -1,032.84% |
Debt/Equity Ratio | 0% |
How did 6838 perform over the long term?
See historical performance and comparison